click to go
Parkinson’s disease - Yahoo Search Results

Parkinson's Disease Treatment Industry - Identifying and Commercializing First-in-Class Innovation New Research Report ...

finance.yahoo.com/news/parkinsons-disease-treatment-industry-identifying-131300650.html

PUNE, India, Feb. 9, 2016 /PRNewswire-iReach/ -- Parkinson' s Disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease, affecting around 7.4...

Parkinson's Disease Market - Pipeline Review, H2 2015 - 150+ Companies and Drug Profiles - Research and Markets

finance.yahoo.com/news/parkinsons-disease-market-pipeline-review-132200131.html

Research and Markets has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2015" report to their offering.

Parkinsons patients trained to respond to placebos

www.nature.com/doifinder/10.1038/nature.2016.19341

Study suggests how dummy pills might reduce drug doses in routine care.

OneRing is a brilliant new wearable designed to monitor Parkinsons Disease tremors

news.yahoo.com/onering-brilliant-wearable-designed-monitor-184435113.html

In his freshman year at Cupertino High School, Utkarsh Tandon won the science fair with a machine learning model that collected and analyzed data on Parkinsons disease. As a...

Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease ...

finance.yahoo.com/news/amarantus-receives-orphan-drug-designation-124500686.html

Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced...

Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease ...

www.prnewswire.com/news-releases/amarantus-receives-orphan-drug-designation-from-the-us-fda-for-eltoprazine-in-the-treatment-of-parkinsons-disease-levodopa-induced-dyskinesia-568296831.html

SAN FRANCISCO, February 10, 2016 /PRNewswire/ -- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative...

Frontier Pharma: Parkinson's Disease - Identifying and Commercializing First-in-Class Innovation

finance.yahoo.com/news/frontier-pharma-parkinsons-disease-identifying-182100437.html

Parkinson' s Disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease, affecting around 7.4 million people worldwide. The current market...

Amarantus Receives Orphan Drug Designation For Eltoprazine

www.bioprocessonline.com/doc/amarantus-receives-orphan-drug-designation-eltoprazine-0001?atc~c=771+s=773+r=001+l=a

Amarantus BioScience Holdings, Inc.(OTCQB: AMBS),a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today...

New Memorial program aims to help people cope with Parkinson's

www.fox28.com/story/31202499/2016/02/11/new-memorial-program-aims-to-help-people-cope-with-parkinsons

More than 10 million people in the country have Parkinson' s disease. They include Mohammed Ali, actor Michael J. Fox and the Reverend Billy Graham. Although the disease is...

AMBS: Amarantus Eltoprazine Granted Orphan Drug Designation for PD-LID

finance.yahoo.com/news/ambs-amarantus-eltoprazine-granted-orphan-150000819.html

Eltoprazine is a small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson' s disease levodopa-induced dyskinesia (PD-LID), adult...